1. Select a treatment
  2. TASCENSO ODT

TASCENSO ODT® (fingolimod)

0.25 mg and 0.5 mg

What is TASCENSO ODT?

TASCENSO orally disintegrating tablet (ODT) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.1

It is the same proven fingolimod you might be familiar with, but it comes in a unique ODT formulation.1

At Cycle, we know that life-changing treatments need life-improving support to match. That’s why we created Cycle Vita, delivering individualized product support every step of the way with TASCENSO ODT.

Tascenso ODT logo
Placeholder Image

Support available to you with TASCENSO ODT

Start your TASCENSO ODT enrollment here

Download and print the enrolment form, share it with your doctor and discuss why you think TASCENSO ODT may be suited to your needs.

Enroll here
The first steps

Your Cycle Vita team will quickly get to work with your insurance provider to help you understand your coverage.

We will coordinate seamlessly between different parties, such as insurance companies, doctors, and pharmacists to help you with your prior authorization and document requirements.

We will route your TASCENSO ODT therapy to the appropriate specialty pharmacy and follow-up to ensure swift shipment of your medication.

Additional assistance, when required, thoughout your journey

Our Cycle Vita team has decades of experience supporting patients with MS.

If you are not currently taking a fingolimod product, eligible patients will require baseline assessments (such as blood work, an ECG or eye exam) prior to taking TASCENSO ODT and a first dose observation the first time you take the product.1 FDOs are available in-home or at a neutral location if necessary, through the TASCENSO Time Program.

Co-pay assistance*

If you have commercial insurance, you may be eligible for the Cycle Vita Co-pay assistance Program. Commercially insured eligible patients may pay as little as $0. Please contact our Access Specialists to find out more about this and other programs that may be available to you (such as the Bridge Program).

If you are taking another fingolimod treatment, a free supply of TASCENSO ODT is available while we secure appropriate benefit verification and prior authorization. It may also be requested if you experience a temporary disruption in therapy due to insurance coverage.

Our Registered Clinicians can provide you with training to help you keep on top of your medication schedule.

Translation services are available on request.

Meet our specialist team

In some cases, an appeal may be needed. Where this is the case, our experienced team will work with your insurer and doctor to understand the requirements and help you with any TASCENSO ODT reimbursement gaps.

If you agree, our proactive team will remind your doctor when your TASCENSO ODT prescription needs to be renewed, in a timely manner, to ensure an uninterrupted supply of your therapy.

What is multiple sclerosis (MS)?

The exact cause of MS is unknown. Scientists believe it is triggered by several different factors and there is ongoing research to identify the exact cause.2

No two MS patients are the same, and symptoms vary from person to person.3 Some of the main symptoms include problems with vision, fatigue, numbness, pain and bowel or bladder problems.3 Not everyone will experience all of these symptoms.

Diagnosis can be life altering and incredibly emotional for you and your family. There’s a lot to take in and think about, and every patient with MS has a different experience. At Cycle Vita, we are here to support you, for life.

Resources

Enrollment Form
Download
PHI Form
Download
Full Prescribing Information
Download
Medication Guide
Download

Footnote
*Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at +1 (888) 360-8482.

TASCENSO ODT® is a registered trademark of Handa Neuroscience, LLC.

References

  1. TASCENSO ODT (fingolimod). Prescribing Information. Cycle Pharmaceuticals Ltd.
  2. National Multiple Sclerosis Society (2022) What Causes MS? Available at https://www.nationalmssociety.org/What-is-MS/What-Causes-MS (Accessed: December 6th 2022)
  3. National Multiple Sclerosis Society (2022) MS Signs & Symptoms. Available at https://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms (Accessed: December 6th 2022)

View

Indication and Important Safety Information: TASCENSO ODT® (fingolimod) 0.25 mg and 0.5 mg

INDICATIONS

TASCENSO ODT is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.

CONTRAINDICATIONS

Do not take TASCENSO ODT if:

  • In the last 6 months you experienced heart attack, unstable angina, stroke or mini-stroke (transient ischemic attack or TIA), or certain types of heart failure;
  • You have an irregular or abnormal heartbeat (arrhythmia), including a heart finding called prolonged QT as seen on an ECG, or if you take medicines that change your heart rhythm.
  • You are allergic to fingolimod or any of the other ingredients.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

TASCENSO ODT may cause serious side effects. TASCENSO ODT can slow your heart rate, therefore you will be monitored after the first dose. There is an increased risk of serious infections, some of which can be life threatening; contact your doctor if you develop any symptoms of infections. You may experience shortness of breath and increased blood pressure. Progressive multifocal leukoencephalopathy, a rare brain infection, has occurred in patients taking fingolimod; call your doctor immediately if you experience symptoms including weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. Macular edema, a vision problem that can cause some of the same vision symptoms as an MS attack may occur; call your doctor immediately if you have any vision changes. TASCENSO ODT may cause liver damage; call your doctor immediately if you experience unexplained nausea, abdominal pain, fatigue, anorexia, jaundice and/or dark urine. Rare cases of Posterior Reversible Encephalopathy Syndrome in adults have been reported with fingolimod; call your doctor immediately if you experience sudden onset of severe headaches, altered mental status, visual disturbances or seizures. TASCENSO ODT may cause harm to your unborn baby; speak to your doctor before becoming pregnant. Stopping TASCENSO ODT may cause worsening of your MS symptoms, consult a doctor before stopping treatment. Malignancies have been associated with fingolimod treatment; limit exposure to sunlight and call your doctor if you have any changes in skin appearance. You may experience a hypersensitivity reaction; call your doctor if you experience rash, urticaria and angioedema. TASCENSO ODT remains in the blood and can continue to have effects up to two months after treatment.

ADVERSE REACTIONS

The most common side effects with fingolimod are headache, abnormal liver tests, diarrhea, cough, flu, inflammation of the sinuses, back pain, stomach pain, and pain in arms and legs.

If you have any new or worsening negative side effects whilst taking TASCENSO ODT you should immediately call your doctor.

Tell your doctor about all your medical conditions and all medicines you take, before starting treatment.

If you take too much TASCENSO ODT immediately call your doctor or go to the nearest hospital emergency room.

For more detailed information, please refer to the full Prescribing Information at: www.tascenso.com/PI

For more detailed information, please refer to the Medication Guide – www.tascenso.com/MG

To report SUSPECTED ADVERSE REACTIONS, contact Cycle Pharmaceuticals Ltd at 1-888-533-1625, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch